August 6, 2026

Consolidated Financial Results for the First Three Months of the Fiscal Year Ending March 31, 2027 (Under Japanese GAAP)

Listed Company: Zeria Pharmaceutical Co., Ltd. (Stock Exchange: Tokyo Stock Exchange)
Code Number: 4559 (URL: https://www.zeria.co.jp/english/)
Representative: Mitsuhiro Ibe, Representative Director, President & COO
Person in charge of reference: Koichi Tamura, Director, Public Relations Division TEL (03) 3661-1039
Scheduled date to commence dividend payments: –
Preparation of supplementary documents to the financial results: None
Holding of financial results presentation: None

(Amounts under a million yen are truncated.)

1. Consolidated Financial Highlights (April 1, 2026 through June 30, 2026)

(1) Consolidated Financial Results (cumulative)

(Percentage figures indicate changes from the same period of the previous year.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
Three months ended	Million yen	%	Million yen	%	Million yen	%	Million yen	%
June 30, 2026	21,448	10.1	1,950	28.3	1,432	(13.8)	866	(20.6)
June 30, 2025	19,489	(9.2)	1,520	(61.4)	1,662	(69.6)	1,090	(74.1)

Note: Comprehensive income: For the three months ended June 30, 2026: 769 million yen [－%]
For the three months ended June 30, 2025: (1,116) million yen [－%]

	Basic earnings per share	Diluted earnings per share
Three months ended	Yen	Yen
June 30, 2026	19.65	–
June 30, 2025	24.75	–

(2) Consolidated Financial Position

	Total assets	Net assets	Equity ratio
As of	Million yen	Million yen	%
June 30, 2026	174,685	108,272	61.8
March 31, 2026	179,697	108,604	60.3

Reference: Equity: As of June 30, 2026: 108,039 million yen As of March 31, 2026: 108,396 million yen

2. Dividends

	Annual dividends				
	First quarter	Second quarter	Third quarter	Year-end	Total
	Yen	Yen	Yen	Yen	Yen
Year ended March 31, 2026	–	24.00	–	25.00	49.00
Year ending March 31, 2027	–				
Year ending March 31, 2027 (Forecast)		25.00	–	25.00	50.00

Note: Revision of the forecast of dividends most recently announced: None

3. Consolidated Financial Forecast for Fiscal Year Ending March 31, 2027 (April 1, 2026 through March 31, 2027)

(Percentage figures indicate changes from the same period of the previous year.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Basic earnings per share
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Yen
First six months	45,000	12.6	6,000	64.8	6,000	125.9	4,000	130.2	90.75
Full year	95,000	6.6	13,000	5.1	13,000	17.7	10,000	18.3	226.86

Note: Revision of the financial forecast most recently announced: None

* Notes

(1) Significant changes in the scope of consolidation during the period: None

Inclusion: – (Company name: –)　　Exclusion: – (Company name: –)

(2) Application of special accounting for preparing the quarterly consolidated financial statements: Yes

Note: For details, please refer to "2. Quarterly Consolidated Financial Statements and Significant Notes Thereto, (3) Notes to quarterly consolidated financial statements (Notes on special accounting methods for preparation of quarterly consolidated financial statements)" on page 8 of the Attached Material.

(3) Changes in accounting policies, changes in accounting estimates, and restatement of prior period financial statements after error corrections

1) Changes in accounting policies due to revisions to accounting standards and other regulations: None
2) Changes in accounting policies due to other reasons: None
3) Changes in accounting estimates: Yes
4) Restatement of prior period financial statements after error corrections: None

Note: For details, please refer to "2. Quarterly Consolidated Financial Statements and Significant Notes Thereto, (3) Notes to quarterly consolidated financial statements (Notes on changes in accounting estimates)" on page 8 of the Attached Material.

(4) Number of shares issued (common shares)

1) Number of shares issued as of the end of the term (including treasury shares):
   As of June 30, 2026: 50,119,190 shares　　As of March 31, 2026: 50,119,190 shares
2) Number of shares of treasury shares as of the end of the term:
   As of June 30, 2026: 6,039,792 shares　　As of March 31, 2026: 6,039,792 shares
3) Average number of shares during the period (cumulative from the beginning of the fiscal year):
   For the three months ended June 30, 2026: 44,079,398 shares
   For the three months ended June 30, 2025: 44,079,486 shares

* Review of the Japanese-language originals of the attached quarterly consolidated financial statements by certified public accountants or an audit corporation: None

* Cautionary Statement with Respect to Appropriate Use of Financial Forecast and Other Special Matters

The description about the future including the projection in this document is based on information available to the Company at present and certain presumptions which the Company considers reasonable. Consequently, any descriptions herein do not constitute assurances regarding actual results by the Company. The actual results for future terms may differ from the information in this document due to various factors. For the assumptions made in financial forecasts and cautions concerning the use thereof, please refer to "1. Summary of Business Results (3) Explanation of consolidated financial forecasts and other forward-looking statements" on page 3 of the Attached Material.

○Table of contents of attachments

1. Summary of Business Results

(1) Summary of business results for the period under review

Net sales for the first three months of the fiscal year ending March 31, 2027 were 21,448 million yen (up 10.1% from the same period of the previous fiscal year). Operating profit was 1,950 million yen (up 28.3% from the same period of the previous fiscal year). On the other hand, due to the occurrence of foreign exchange losses caused by the appreciation of the Swiss franc against European currencies such as the euro and British pound, ordinary profit was 1,432 million yen (down 13.8% from the same period of the previous fiscal year), and profit attributable to owners of parent was 866 million yen (down 20.6% from the same period of the previous fiscal year).

Below are the results by business segment.

(i) *Ethical Pharmaceuticals Business*

In overseas markets, sales continued to be favorable, centering on our mainstay product Asacol. In the domestic market, sales were also strong, due in part to our further focus on market penetration of Veltassa, a therapeutic agent for hyperkalemia launched in March of last year.

As a result, net sales in the business amounted to 14,379 million yen (up 13.5% from the same period of the previous fiscal year).

(ii) *Consumer Healthcare Business*

Sales of the mainstay products, Chondroitin range and the WithOne range decreased due to the impact of competing products and other factors amidst a slowdown in the growth of the overall OTC pharmaceutical market. On the other hand, sales of the Hepalyse range grew mainly driven by the Hepalyse W range for convenience stores, due in part to the effect of active advertising and promotional activities.

As a result, net sales in the business amounted to 7,032 million yen (up 3.6% from the same period of the previous fiscal year).

(iii) *Other*

Net sales in this segment amounted to 37 million yen (down 3.6% from the same period of the previous fiscal year), mainly due to insurance agency business and real estate lease revenue.

(2) Overview of financial position for the period under review

Total assets at the end of the first quarter of the fiscal year ending March 31, 2027 were 174,685 million yen, a decrease of 5,012 million yen from the end of the previous fiscal year. Current assets decreased 2,871 million yen to 79,775 million yen from the end of the previous fiscal year, and non-current assets decreased 2,141 million yen to 94,909 million yen from the end of the previous fiscal year. Major changes in current assets included a decrease of 5,072 million yen in accounts receivable - trade and an increase of 1,631 million yen in inventories such as merchandise and finished goods. In addition, the main change in non-current assets was a decrease of 1,159 million yen in intangible assets.

Total liabilities at the end of the quarter under review were 66,413 million yen, a decrease of 4,680 million yen from the end of the previous fiscal year. Current liabilities decreased 4,216 million yen to 51,491 million yen from the end of the previous fiscal year, and non-current liabilities decreased 463 million yen to 14,921 million yen from the end of the previous fiscal year. Major changes in current liabilities were a decrease of 2,555 million yen in short-term borrowings and a decrease of 1,822 million yen in income taxes payable. The main change in non-current liabilities was a decrease of 392 million yen in other non-current liabilities, including a decrease in deferred tax liabilities.

Net assets at the end of the quarter under review were 108,272 million yen, a decrease of 332 million yen from the end of the previous fiscal year. This was mainly due to the recording of profit attributable to owners of parent of 866 million yen and the payment of 1,101 million yen as dividends declared at the end of the previous period.

As a result, the equity ratio at the end of the quarter under review increased by 1.5 percentage points from the end of the previous fiscal year to 61.8%.

(3) Explanation of consolidated financial forecasts and other forward-looking statements

With regard to the business results for the first three months of the fiscal year ending March 31, 2027, net sales and operating profit progressed largely in line with our business plan. On the other hand, ordinary profit and profit attributable to owners of parent fell below the planned progress due to the impact of the foreign exchange losses incurred.

As business results are expected to progress largely in line with the plan in the second quarter and beyond, the consolidated financial forecasts announced on May 8, 2026 remain unchanged at this time. In addition, due to the uncertainty of future trends in foreign exchange rates, the occurrence of foreign exchange gains or losses is not factored in.

2. Quarterly Consolidated Financial Statements and Significant Notes Thereto

(1) Quarterly consolidated balance sheet

(Thousands of yen)

	As of March 31, 2026	As of June 30, 2026
Assets		
Current assets		
Cash and deposits	27,760,027	27,706,168
Electronically recorded monetary claims - operating	35,486	98,122
Accounts receivable - trade	31,413,406	26,341,253
Merchandise and finished goods	10,994,264	11,154,626
Work in process	3,551,515	4,590,111
Raw materials and supplies	6,351,030	6,783,198
Other	3,200,118	3,750,210
Allowance for doubtful accounts	(658,965)	(647,823)
Total current assets	82,646,882	79,775,867
Non-current assets		
Property, plant and equipment		
Buildings, net	6,925,036	6,906,840
Land	12,663,993	12,664,226
Other, net	8,010,353	7,815,975
Total property, plant and equipment	27,599,383	27,387,042
Intangible assets		
Goodwill	3,027,507	2,837,447
Sales right	27,088,898	25,925,705
Other	9,465,382	9,659,214
Total intangible assets	39,581,788	38,422,367
Investments and other assets		
Investment securities	10,112,376	9,504,790
Retirement benefit asset	19,294,530	19,133,200
Other	492,075	490,846
Allowance for doubtful accounts	(29,086)	(28,859)
Total investments and other assets	29,869,895	29,099,977
Total non-current assets	97,051,067	94,909,387
Total assets	179,697,949	174,685,255
Liabilities		
Current liabilities		
Accounts payable - trade	4,895,991	5,733,835
Short-term borrowings	33,834,190	31,278,390
Income taxes payable	4,827,849	3,005,787
Provision for bonuses	1,778,324	1,685,408
Other	10,371,773	9,788,280
Total current liabilities	55,708,129	51,491,702
Non-current liabilities		
Long-term borrowings	5,269,740	5,195,830
Retirement benefit liability	201,368	203,717
Asset retirement obligations	56,629	56,665
Other	9,857,290	9,465,103
Total non-current liabilities	15,385,029	14,921,317
Total liabilities	71,093,159	66,413,019

(Thousands of yen)

	As of March 31, 2026	As of June 30, 2026
Net assets		
Shareholders’ equity		
Share capital	6,593,398	6,593,398
Capital surplus	5,620,541	5,620,541
Retained earnings	73,545,791	73,310,004
Treasury shares	(12,204,622)	(12,204,622)
Total shareholders’ equity	73,555,108	73,319,321
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	3,069,779	2,696,576
Foreign currency translation adjustment	24,628,069	25,128,750
Remeasurements of defined benefit plans	7,143,784	6,894,524
Total accumulated other comprehensive income	34,841,632	34,719,852
Non-controlling interests	208,048	233,062
Total net assets	108,604,790	108,272,235
Total liabilities and net assets	179,697,949	174,685,255

(2) Quarterly consolidated statement of income and quarterly consolidated statement of comprehensive income

Quarterly consolidated statement of income

(Thousands of yen)

	Three months ended June 30, 2025	Three months ended June 30, 2026
Net sales	19,489,789	21,448,542
Cost of sales	5,578,659	6,217,179
Gross profit	13,911,129	15,231,362
Selling, general and administrative expenses	12,390,593	13,280,600
Operating profit	1,520,535	1,950,762
Non-operating income		
Interest income	28,523	20,108
Dividend income	250,745	284,925
Other	71,946	36,643
Total non-operating income	351,215	341,677
Non-operating expenses		
Interest expenses	121,866	132,042
Foreign exchange losses	32,524	643,617
Other	54,952	83,917
Total non-operating expenses	209,343	859,577
Ordinary profit	1,662,408	1,432,861
Extraordinary losses		
Loss on sale of non-current assets	22	—
Loss on retirement of non-current assets	2,790	0
Total extraordinary losses	2,812	0
Profit before income taxes	1,659,595	1,432,861
Income taxes	624,618	547,567
Profit	1,034,976	885,293
Profit (loss) attributable to non-controlling interests	(55,775)	19,096
Profit attributable to owners of parent	1,090,752	866,197

Quarterly consolidated statement of comprehensive income

(Thousands of yen)

	Three months ended June 30, 2025	Three months ended June 30, 2026
Profit	1,034,976	885,293
Other comprehensive income		
Valuation difference on available-for-sale securities	293,532	(373,202)
Foreign currency translation adjustment	(2,265,020)	506,555
Remeasurements of defined benefit plans, net of tax	(180,242)	(249,259)
Total other comprehensive income	(2,151,731)	(115,906)
Comprehensive income	(1,116,754)	769,387
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	(1,044,600)	744,417
Comprehensive income attributable to non-controlling interests	(72,153)	24,970

(3) Notes to quarterly consolidated financial statements

(Notes on changes in accounting estimates)

Regarding the sales right for the product DIFICLIR held by the Company's subsidiary Tillotts Pharma AG, the Company has been amortizing it by estimating the useful life based on the period over which economic benefits are expected to be generated. However, due to an increased possibility of generic drug entry in the future, the useful life has been shortened, and this change is being applied prospectively.

As a result, operating profit, ordinary profit and profit before income taxes for the first three months of the current fiscal year each decreased by 388,569 thousand yen.

(Notes on special accounting methods for preparation of quarterly consolidated financial statements)

Calculation of tax expenses

Tax expenses were calculated by reasonably estimating the effective tax rate after applying tax effect accounting to the profit before income taxes for the fiscal year that includes the first quarter of the current fiscal year and multiplying profit before income taxes by such estimated effective tax rate.

(Notes on segment information, etc.)

[Segment information]

I First three months of the previous fiscal year (from April 1, 2025 to June 30, 2025)

1. Information on net sales and profit or loss by reportable segment

(Thousands of yen)

	Reportable segment			Other (Note 1)	Total	Adjustment (Note 2)	Amount recorded in quarterly consolidated statement of income (Note 3)
	Ethical Pharmaceuticals Business	Consumer Healthcare Business	Total				
Net sales							
Sales to external customers	12,666,534	6,784,797	19,451,332	38,457	19,489,789	–	19,489,789
Intersegment sales and transfers	–	44	44	121,291	121,336	(121,336)	–
Total	12,666,534	6,784,842	19,451,376	159,748	19,611,125	(121,336)	19,489,789
Segment profit	1,716,469	1,336,663	3,053,133	54,203	3,107,336	(1,586,800)	1,520,535

(Notes) 1. "Other" is a business segment not included in the reportable segments and includes the insurance agency business and real estate business.

2. Adjustment of segment profit of (1,586,800) thousand yen is mainly corporate expenses, such as general and administrative expenses that are not allocated to reportable segments.

3. Segment profit is adjusted with operating profit in the quarterly consolidated statement of income.

2. Information on impairment losses on non-current assets or goodwill by reportable segment

Not applicable.

II First three months of the current fiscal year (from April 1, 2026 to June 30, 2026)

1. Information on net sales and profit or loss by reportable segment

(Thousands of yen)

	Reportable segment			Other (Note 1)	Total	Adjustment (Note 2)	Amount recorded in quarterly consolidated statement of income (Note 3)
	Ethical Pharmaceuticals Business	Consumer Healthcare Business	Total				
Net sales							
Sales to external customers	14,379,128	7,032,358	21,411,486	37,055	21,448,542	–	21,448,542
Intersegment sales and transfers	–	49	49	117,363	117,412	(117,412)	–
Total	14,379,128	7,032,407	21,411,536	154,418	21,565,954	(117,412)	21,448,542
Segment profit	2,195,496	1,362,106	3,557,603	54,377	3,611,981	(1,661,218)	1,950,762

(Notes) 1. "Other" is a business segment not included in the reportable segments and includes the insurance agency business and real estate business.

2. Adjustment of segment profit of (1,661,218) thousand yen is mainly corporate expenses, such as general and administrative expenses that are not allocated to reportable segments.

3. Segment profit is adjusted with operating profit in the quarterly consolidated statement of income.

2. Information on impairment losses on non-current assets or goodwill by reportable segment

Not applicable.

(Notes on significant changes in the amount of shareholders' equity)

Not applicable.

(Notes on premise of a going concern)

Not applicable.

(Notes on quarterly consolidated statements of cash flows)

The quarterly consolidated statements of cash flows have not been prepared for the first three months of the current fiscal year. Depreciation (including amortization related to intangible assets excluding goodwill) and amortization of goodwill for the first three months are as follows.

(Thousands of yen)

	First three months of the previous fiscal year (from April 1, 2025, to June 30, 2025)	First three months of the current fiscal year (from April 1, 2026, to June 30, 2026)
Depreciation	1,572,320	2,104,706
Amortization of goodwill	176,717	184,284

3. Supplemental Information

(1) Sales of major products and merchandise Consolidated

(Thousands of yen)

	First three months of the previous fiscal year (from April 1, 2025 to June 30, 2025)	First three months of the current fiscal year (from April 1, 2026 to June 30, 2026)	Percentage change (%)
1. Ethical Pharmaceuticals Business	12,666,534	14,379,128	13.5
Asacol	4,852,014	5,720,374	17.9
DIFICLIR	4,569,779	4,976,854	8.9
Entocort	977,118	1,055,091	8.0
Acofide	808,525	797,646	(1.3)
Other	1,459,096	1,829,161	25.4
2. Consumer Healthcare Business	6,784,797	7,032,358	3.6
Hepalyse range	3,065,961	3,215,615	4.9
Chondroitin range	1,380,904	1,310,561	(5.1)
WithOne range	370,028	348,699	(5.8)
Other	1,967,903	2,157,482	9.6
3. Other Business	38,457	37,055	(3.6)
Total	19,489,789	21,448,542	10.1

(2) Status of pipeline of new drugs

I. Domestic

As of August 6, 2026

Stage	Development Code/ Generic Name	Development	Indications	Classification	Origin
Phase III	Z-338/Acotiamide	Zeria	Pediatric functional dyspepsia	Upper gastrointestinal motility modulator	Original
Phase II	ZG-802/Acotiamide	Zeria	Underactive bladder	Lower urinary tract function modulator	Original
Phase II (Specified Clinical Trial)	Z-100	Nonprofit Organization, North East Japan Study Group	Non-small cell lung cancer	Immunomodulator	Original

II. Overseas

Stage	Development Code/ Generic Name	Development	Indications	Classification	Origin
NDA approved (Nicaragua, Costa Rica)	Z-338/Acotiamide	Faes Farma	Functional dyspepsia	Upper gastrointestinal motility modulator	Original (Out-licensed)
NDA filed (Vietnam)	Z-338/Acotiamide	Pharmaceutical Joint Stock Company of February 3rd	Functional dyspepsia	Upper gastrointestinal motility modulator	Original
NDA filed (Colombia, Panama)	Z-338/Acotiamide	Faes Farma	Functional dyspepsia	Upper gastrointestinal motility modulator	Original (Out-licensed)
Phase III (Europe, United States, Canada)	Z-338/Acotiamide	Agastra-Lab s.r.l.	Functional dyspepsia	Upper gastrointestinal motility modulator	Original (Out-licensed)